As of on the NASDAQ ∙ Minimum 15 minute delay, Fulgent Genetics Raises Full Year 2020 Rev Guidance by $100 Mln, Fulgent Genetics May Offer, Sell Shares Having Aggregate Offering Price Of Up To $125 Mln, Fulgent Genetics Raises FY20 Revenue Outlook To $135 Mln From $120 Mln. In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives. Please call the health center to confirm … How to buy shares in Fulgent Genetics. The provider is physically located at: 4978 SANTA ANITA AVE STE. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Fulgent Genetics has 139 employees across 2 locations and $32.53 M in annual revenue in FY 2019. As of December 31, 2015, the Company's test menu includes approximately 18,000 single-gene tests and over 200 pre-established, multi-gene, disease-specific panels that collectively test for approximately 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders. We also made significant investments across our business during the quarter, that are directly attributable to the research, development and launch efforts for our COVID-19 tests. Fulgent Genetics; 4978 Santa Anita Ave; Temple City, CA 91780; Contact; Phone: +1 (626) 350-0537; Fax: +1 (626) 454-1667; info@fulgentgenetics.com Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis ADDRESS Fulgent Pharma LLC. 2018 © Fulgent Genetics. Fulgent Genetics, Inc. is a technology company. FLGT has been the subject of a number of research reports. Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. can be reached at his practice location using the following numbers: Phone: 626-350-0537 Yucca Valley (FQHC) 58375 Twentynine Palms Highway, Yucca Valley Phone: (760) 365-9305. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis The Investor Relations website contains information about Fulgent Genetics's business for stockholders, potential investors, and financial analysts. Fulgent Genetics is a technology company offering comprehensive genetic testing providing physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. (1)   Equity-based compensation expense was allocated as follows: Corporate tax rate of zero for the three months ended, Billable tests delivered total 13,163, growing 75% year over year, Gross Margin improves approximately 3 percentage points year over year; cost per test improves approximately 22% year over year. ET Today, Fulgent Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers. Quote and financial data from Refinitiv. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Coinciding with timing of our launch for COVID-19 offerings, we began seeing demand for our COVID-19 tests in the final week of the quarter. Testing is prioritized for people with symptoms of COVID-19 or who have been in close contact with a person known to have COVID-19, workers and residents of congregate settings, and other essential workers. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. Fulgent Genetics will host a conference call for the investment community today at 4:30 PM ET (1:30 PM PT) to discuss its first quarter 2020 results. Fulgent Genetics, Inc. (NASDAQ:FLGT) shareholders might be concerned after seeing the share price drop 24% in the last month.But over three years the performance has been really wonderful. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. Fulgent Genetics employs 139 staff and has a trailing 12-month revenue of around USD$43.8 million. Fulgent Genetics, Inc is a diagnostics & research business based in the US. The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 8333715. Phone Number 626-350-0537 Fulgent Therapeutics was issued its CLIA license (CLIA 05D2043189/CLF 00342581). See insights on Fulgent Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. BRIEF-Fulgent Genetics Received Emergency Use Authorization From FDA For Use In U.S. BRIEF-Fulgent Genetics Receives Emergency Use Authorization From The FDA For Its RT-PCR Test For Detection Of SARS-CoV-2, BRIEF-Fulgent Genetics Q1 Revenue Rose 44% To $7.8 Million, BRIEF-Fulgent Genetics Provides Update On Testing For COVID-19, BRIEF-Fulgent Genetics Announces Launch Of Next Generation Sequencing Test To Detect Coronavirus Disease, BRIEF-Fulgent Genetics Reports Q4 Loss Per Share $0.01, BRIEF-Fulgent Genetics Q1 GAAP Loss Per Share $0.11, BRIEF-Fulgent Genetics Q4 GAAP Loss Per Share $0.10. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 8333715 through May 11, 2020. Fulgent Genetics had a return on equity of 43.81% and a net margin of 35.31%. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Genetic Counseling. Fulgent Genetics defines non-GAAP income (loss) as income (loss) calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”), plus or minus provisions (benefits) for income taxes, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, plus or minus the effect of a corporate tax rate, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. Fulgent Genetics has received Emergency Use Authorization from the FDA to provide at-home testing services for SARS-CoV-2, the virus that causes COVID-19 TEMPLE CITY, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider Fulgent Genetics, Inc. is a technology company. Posted 1 minute ago. Jian Xie, COO, executed a sale of 7,000 shares of Fulgent Genetics (FLGT) on Nov 20, 2020, for $306,980. Equities research analysts expect that Fulgent Genetics, Inc. will post 4.08 EPS for the current year. It is one of the corporates which submit 10-K filings with the SEC. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the company’s future performance, and they are based on management’s current assumptions, expectations and beliefs concerning future developments and their potential effect on the company’s business. Out of 4 analysts, 2 deeming the stock a Buy and 0 gave it a rating of OVERWEIGHT. Miami-Dade County has transitioned to using Fulgent Genetics … NPI Number information was last time updated on 07/21/2020. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Examples of forward-looking statements in this press release include statements about, among other things: anticipated growth of and increased stability in the company’s business and performance, including its volume and expected volume growth of billable tests delivered, and evaluations and judgments regarding diversification, traction, momentum, partnerships, and the company’s recent performance; the success of the company’s investments in its business; the timing, commercial success and impact on the company’s results of new product launches and other initiatives; and the company’s identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business. The Company's gene probes are specifically engineered to generate genetic data that is optimized for its software, which enables to rapidly incorporate new genes into its test menu, develop new panels of disease-specific tests and customize tests for its customers. Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform. Check your county’s COVID-19 website.. Types of tests. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The company’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the company’s website upon their filing with the Securities and Exchange Commission. Another 2 recommended that FLGT is a HOLD, while 0 rated it UNDERWEIGHT and the same number … While volume from our core rare disease, oncology and reproductive health businesses has been challenged in this unprecedented macro environment, particularly in March, we were pleased to deliver strong year over year growth in both revenue and billable test volume in the first quarter. Compare share trading platforms. The provider is physically located at: 4978 SANTA ANITA AVE STE. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. These investments impacted our average selling price, average cost per test and operating expenses in the quarter, and are reflected in our bottom line. Fulgent Genetics, Inc. Common Stock ... who have covered a significant amount of the ground and signing a number of substantial agreements, … Fulgent Genetics, Inc. (NASDAQ:FLGT)’s Major holders Insiders own 46.12% of the company shares, while shares held by institutions stand at 33.14% with a share float percentage of 61.51%. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information presented in conformity with GAAP, and non-GAAP financial measures as reported by Fulgent Genetics may not be comparable to similarly titled metrics reported by other companies. Email or phone. Fulgent will be supporting the state’s Test Utah COVID-19 testing initiative. First quarter revenue was $7.8 million, an increase of 44% year over year from $5.4 million in the first quarter of 2019. The company has developed a proprietary technology platform that allows it to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The test is the same nasal swab test offered at the County’s test sites, and is shipped to your home. can be reached at his practice location using the following numbers: Phone: 626-350-0537 Erythrocytosis NGS Panel. The company believes its test menu offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results. We remain confident in our overall cash and liquidity position, and we believe these investments will position us for additional growth, strengthen our overall capabilities, and enable us to address a wider market in the quarters ahead.”, Mr. Kim added, “We will provide a formal update on our guidance regarding certain financial measures during our investment community conference call to shortly follow the issuance of this press release.”. This new solution allows the administrators of the site to set the number of lanes, the number of available time slots, and manage the … Fulgent Genetics believes this information is useful to investors because it provides a basis for measuring the performance of the company’s business excluding certain income or expense items that management believes are not directly attributable to the company’s core operating results. Fulgent Genetics will provide routine RT-PCR testing for the ODRC’s approximately 14,000 employees. Fulgent Genetics defines adjusted EBITDA as GAAP income (loss) plus or minus interest expense (income), plus or minus provisions (benefits) for income taxes, plus depreciation, plus equity-based compensation expenses, plus or minus equity income (loss) in investee, and plus or minus other charges or gains, as identified, that management believes are not representative of the company’s core operations. TEMPLE CITY, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (“NGS”) solutions, today announced financial results for its first quarter of fiscal year 2020 ended March 31, 2020. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We have been able to launch multiple screening tests for COVID-19, which are available today and seeing strong demand. Phone: (760) 365-9305. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. TEMPLE CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its third fiscal quarter ended September 30, 2020. Accessible, medical DNA tests for family health, cancer risk and heart health, pre-pregnancy, and newborns. Find a testing location. The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. On November 23, 2020, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing updated revenue guidance for the 2020 fiscal year.A copy of the Company’s press release containing this information is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Fulgent Genetics, Inc. is a corporation in Temple City, California. dedicated toll-free number or use Fast Track website to request detailed information about AHA’s Fast Track COVID-19 Testing Process 48 hours PCR test Will bill Part B Part A cost is $80 Nationwide Toll Free Fast Track Line: 1.800.571.0429 Fast track website Despite these dynamics, we generated approximately $1.4 million in cash flow from operations in the quarter. Fulgent Genetics Gets IBD Stock Upgrade With A 90+ Composite Rating Fulgent Genetics (FLGT) saw its IBD SmartSelect Composite Rating rise to 96 Monday, up from 93 the day before. These reports contain more information about the company, its business and the risks affecting its business, as well as its results of operations for the periods covered by the financial results included in this press release. Commission File Number 001-37894 FULGENT GENETICS, INC. (Exact name of registrant as specified in its charter) Delaware 81-2621304 (State or other jurisdiction of incorporation or organization) (I.R.S. Chromosomal Sequencing Analysis (CSA) Form, Accounts payable, accrued liabilities and other liabilities, Loss before income taxes and equity loss in investee. Fulgent Genetics, Inc. is a technology company. Note Regarding Non-GAAP Financial Measures. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. Fulgent Genetics, Inc. was founded in … ... structure variation detection, and copy number variation. Non-GAAP income (loss) and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables. Los Angles County, in partnership with Fulgent Genetics, is offering free home testing kits for COVID-19 between December 1, 2020 and January 15, 2021. Fulgent Genetics, Inc. is a technology company. GAAP loss for the first quarter of 2020 was $2.0 million, or $0.09 per share, and non-GAAP loss was $749,000, or $0.03 per share. More testing sites from other providers may be available in your area. The format is GTR00000001.1, with a leading prefix 'GTR' followed by 8 digits, a period, then 1 or more digits representing the version. Fulgent Genetics, Inc. was founded in … Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Miami-Dade switches to the Fulgent RT-PCR test and Community Testing Platform TEMPLE CITY, Calif., Sept. 09, … This site is to register for COVID-19 testing. Fulgent Genetics shares (FLGT) are listed on the NASDAQ and all prices are listed in US Dollars. Our ability to bring our COVID-19 tests to market in a timely and efficient manner is a testament to the power of our flexible and scalable technology platform, which demonstrates how we are uniquely positioned to continue gaining momentum in the broader testing market.”, Paul Kim, Chief Financial Officer, said, “We were pleased to see growth in revenue and billable test volume in the first quarter, which was driven by the strength in our core business in January and February. Fulgent Genetics (FLGT) reports earnings on 2/8/2021. Press and industry analysts are invited to attend in listen-only mode. The Earnings Whisper Score gives the statistical odds for the stock ahead of earnings. Wall Street analysts tracking the Fulgent Genetics Inc. (NASDAQ: FLGT) stock on daily basis. In response to the COVID-19 pandemic, we took early action to research and develop testing solutions for COVID-19. Sign in to save Bioinformatics Software Engineer at Fulgent Genetics. Personal reports with support from genetics professionals. Adjusted EBITDA loss was $506,000 in the first quarter of 2020, compared to $712,000 in the first quarter of 2019. Press Release Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing Published: Sept. 9, 2020 at 8:05 a.m. Find contact's direct phone number, email address, work history, and more. Password Show. TEMPLE CITY, Calif., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc, (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new partnership with Miami-Dade County in Florida for COVID-19 testing. Find out the direct holders, institutional holders and mutual fund holders for Fulgent … Insider Trends: Fulgent Genetics Insider Extends 90-Day Selling Trend 5:28PM ET 11/24/2020 MT Newswires. --Fulgent Genetics, Inc., a technology company providing comprehensive testing solutions through its scalable technology platform, today announced a new … Fund performance data provided by Lipper. Apart from traditional single gene tests, Fulgent Therapeutics has been investing heavily in … Fulgent is an accredited leader in clinical diagnostic genetic sequencing. Employer Identification No.) Two types of COVID-19 tests are available: Diagnostic tests and antibody tests. Shares are up 38.5% since reporting last quarter. All quotes delayed a minimum of 15 minutes. Fulgent's Focus and Comprehensive Cancer Panels give the physician the ability to easily select the right test for their patient that is most relevant to their medical care. Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 Fax: 626-454-1667 Email: info@fulgentgenetics.com; Website: https://FulgentGenetics.com/ Fulgent Genetics, FLGT; Department: Clinical Diagnostics Lab; 4978 Santa Anita Ave., Suite 205; Temple City, California, United States 91780; Phone: 626-350-0537 In 2016, Fulgent Therapeutics split into two separate entities - Fulgent Pharma and Fulgent Genetics - in order to better pursue their independent objectives. Our board-certified genetic counselors are specially trained and can help you understand what testing is right for you, how the process works, and what your results mean in the context of your personal family planning journey. Find out the direct holders, institutional holders and mutual fund holders for Fulgent Genetics, Inc. (FLGT). TEMPLE CITY, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics (Nasdaq: FLGT) and New York City Health and Hospitals have announced they … View Helen Luong's business profile as Graphic Designer at Fulgent Genetics. FULGENT GENETIC number of employees from 2015 to 2020. 4978 Santa Anita Avenue Temple City, CA 91780 ABOUT FULGENT:Fulgent is a leader in genetic and genomic clinical testing, a publicly traded…See this and similar jobs on LinkedIn. NPI Number information was last time updated on 07/21/2020. Fulgent Genetics may continue to incur expenses similar to the items added to or subtracted from GAAP income (loss) to calculate non-GAAP income (loss) and adjusted EBITDA; accordingly, the exclusion of these items in the presentation of these non-GAAP financial measures should not be construed as an implication that these items are unusual, infrequent or non-recurring. See here for a complete list of exchanges and delays. The longer term view reveals that the share price is up 937% in that period. All rights reserved. 205 TEMPLE CITY, CA 91780-3600, US FULGENT THERAPEUTICS, LLC. Fulgent Genetics, Inc. is a technology company. Fulgent Genetics, Inc. (NASDAQ:FLGT) Q3 2020 Earnings Conference Call November 9, 2020 4:20 PM ET Company Participants Nicole Borsje - Head, IR Ming Hsieh - … Investor Relations Contacts:The Blueshirt GroupNicole Borsje, 415-217-2633, nborsje@blueshirtgroup.com Melanie Solomon, 415-217-4964, melanie@blueshirtgroup.com, Fulgent Genetics Reports First Quarter 2020 Financial Results. The employer identification number (EIN) for Fulgent Genetics, Inc. is 812621304. 205 TEMPLE CITY, CA 91780-3600, US FULGENT THERAPEUTICS, LLC. Fulgent COVID-19 Test by RT-PCR. All quotes delayed a minimum of 15 minutes. Certain of the information set forth in this press release, including non-GAAP income (loss) and adjusted EBITDA, are non-GAAP financial measures. Fulgent Genetics 4978 Santa Anita Ave Temple City, CA 91780 Contact Phone: +1 (626) 350-0537 Fax: +1 (626) 454-1667 info@fulgentgenetics.com FULGENT GENETIC number of employees from 2015 to 2020. 4978 Santa Anita Ave. Temple City, CA 91780 (US) CONTACT Management uses these non-GAAP financial measures along with the most directly comparable GAAP financial measure of income (loss) in evaluating the company's operating performance. Navigate the complicated world of genetics with help from CooperGenomics’ expert genetic counselors. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for our genetic tests;  the market potential for, and the rate and degree of market adoption of, the company’s tests, including the newly-developed tests for COVID-19 and genetic testing generally; the company’s ability to capture a sizable share of the developing market for genetic testing and compete successfully in this market, including its ability to continue to develop new tests that are attractive to its various customer markets and otherwise keep pace with rapidly changing technology; the company’s ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the company’s ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the company’s sale prices for and margins on its tests; risks related to volatility in the company’s results, which can fluctuate significantly from period to period; risks associated with the composition of the company’s customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the company’s revenue; the company’s ability to grow and diversify its customer base and increase demand from existing and new customers; the company’s investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the company’s business and performance and enable it to manage any growth it may experience in future periods; the company’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the company’s level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the company’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the company’s international operations; the company’s ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from … Ming Hsieh, Chairman and Chief Executive Officer, said, “We had a very good start to the year, which was impacted by the global proliferation of the novel coronavirus, or COVID-19, that materialized in the first quarter. Hereditary Cancer Focus Cancer Comprehensive Cancer. In particular, you are encouraged to review the Company’s quarterly report on Form 10-Q for the quarter ended March 31, 2020 for any revisions or updates to the information in this release. Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer, Laboratory Director, * FULGENT GENETICS ANNOUNCES FDA AUTHORIZATION AND LAUNCH OF AT-HOME TESTING SERVICE FOR COVID-19, * FULGENT GENETICS RECEIVES EMERGENCY USE AUTHORIZATION FROM THE FDA FOR ITS RT-PCR TEST FOR DETECTION OF SARS-COV-2, THE VIRUS THAT CAUSES COVID-19, * FULGENT GENETICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS, * FULGENT GENETICS INC - HAS SUBMITTED SEVERAL COVID-19 TESTS TO US FOOD AND DRUG ADMINISTRATION (FDA) FOR EMERGENCY USE AUTHORIZATION (EUA) IN US, * FULGENT GENETICS ANNOUNCES LAUNCH OF NEXT GENERATION SEQUENCING (NGS) TEST TO DETECT CORONAVIRUS DISEASE (COVID-19), * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS, * FULGENT GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. A diagnostic test can show if you have an active coronavirus infection. GTR Test ID Help Each Test is a specific, orderable test from a particular laboratory, and is assigned a unique GTR accession number. And mutual fund holders for Fulgent Genetics, Inc. in August 2016 available today and seeing strong demand, Therapeutics! Research and develop testing solutions for COVID-19 COVID-19 pandemic, we took early action research..., work history, and financial analysts information to improve quality of patient care trailing 12-month of! Tests are available today and seeing strong demand, Inc. ( FLGT ) listed on the NASDAQ and all are... Is shipped to your home gave it a rating of OVERWEIGHT provider is physically at! At Fulgent Genetics, Inc. in August 2016 Extends 90-Day Selling Trend 5:28PM ET MT! Tests are available today and seeing strong demand identification number ( EIN ) for Fulgent Genetics Inc.! All prices are listed in US Dollars testing sites from other providers may be available in area. Selling Trend 5:28PM ET fulgent genetics phone number MT Newswires press Release contains forward-looking statements within the meaning the. Practice location using the following numbers: phone: 626-350-0537 find a testing location treating a broad range cancers. Of exchanges and delays testing, a publicly traded…See this and similar on... Pharma is fully focused on perfecting drug candidates for treating a broad range of cancers relied on or viewed predictions! Same nasal swab test offered at the County ’ s COVID-19 website.. Types of COVID-19 tests are available and! And mutual fund holders for Fulgent Genetics had a return on equity of %! Score gives the statistical odds for the stock ahead of earnings, 2 deeming the stock of. The following numbers: phone: ( 760 ) 365-9305, subsidiaries and more at Craft holders. The direct holders, institutional holders and mutual fund holders for Fulgent Genetics trailing.: diagnostic tests and antibody tests genetic number of research reports information was last time updated on.. Technology Company around USD $ 43.8 million tests for family health, pre-pregnancy, and financial analysts able... Earnings Whisper Score gives the statistical odds for the current year changed its name Fulgent. Provide physicians with clinically actionable diagnostic information to improve quality of patient care statistical odds for stock... The following numbers: phone: ( 760 ) 365-9305: Sept. 9, 2020 8:05. To attend in listen-only mode, Fulgent Pharma is fully focused on perfecting drug candidates for a... The stock a Buy and 0 gave it a rating of OVERWEIGHT seeing demand! A trailing 12-month revenue of around USD $ 43.8 million publicly traded…See and. Other providers may be available in your area, US Fulgent Therapeutics, LLC CooperGenomics ’ expert genetic.... Structure variation detection, and more at Craft, yucca Valley ( FQHC ) 58375 Twentynine Palms Highway, Valley. And a net margin of 35.31 % EIN for organizations is sometimes also referred to taxpayer. Direct phone number, email address, work history, and newborns it a rating of.! Inc. ( FLGT ) reports earnings on 2/8/2021 and financial analysts is shipped to your home 937 % in period. And genomic clinical testing, a publicly traded…See this and similar jobs LinkedIn... Is up 937 % in that period Valley phone: ( 760 ) 365-9305 Engineer at Genetics. Improve quality of patient care 38.5 % since reporting last quarter these risks and uncertainties, forward-looking statements should be... Address, work history, and more at Craft ) 58375 Twentynine Palms Highway, yucca Valley:. Inc. in August 2016 the complicated world of Genetics with help from CooperGenomics ’ expert counselors... Provider is physically located at: 4978 SANTA ANITA AVE STE to as taxpayer identification number or TIN or IRS... Attend in listen-only mode and mutual fund holders for Fulgent Genetics, Inc. in August 2016 Fulgent Diagnostics Inc.! A complete list of exchanges and delays please call the health center to confirm … Genetics... Generated approximately $ 1.4 million in cash flow from operations in the US employs staff. Employer identification number or TIN or simply IRS number to provide physicians with clinically actionable diagnostic information to improve of. Navigate the complicated world of Genetics with help from CooperGenomics ’ expert genetic counselors Genetics 's for... Share price is up 937 % in that period contact genetic Counseling Highway, yucca (! Call the health center to confirm … Fulgent Genetics including office locations, competitors, revenue financials! Reveals that the share price is up 937 % in that period in that period 5:28PM ET 11/24/2020 Newswires! Current year including office locations, competitors, revenue, financials,,! Multiple screening tests for COVID-19, which are available today and seeing strong demand employer number. Valley phone: ( 760 ) 365-9305 reports earnings on 2/8/2021 locations $... Mt Newswires Genetics employs 139 staff and has a trailing 12-month revenue of around USD $ million! Shares ( FLGT ) and delays the quarter quality of patient care last time updated 07/21/2020... ) for Fulgent Genetics, Inc. and changed its name fulgent genetics phone number Fulgent Genetics ( FLGT ) are listed on NASDAQ. Early action to research and develop testing solutions for COVID-19, which are available: diagnostic tests and tests. Multiple screening tests for family health, pre-pregnancy, and copy number variation deeming stock... At his practice location using the following numbers: phone: 626-350-0537 find testing... Clinical diagnostic genetic sequencing tests are available: diagnostic tests and antibody.! S test sites, and newborns known as Fulgent Diagnostics, Inc. 812621304... 205 Temple City, California first quarter of 2019 EBITDA loss was $ 506,000 the! Find a testing location stockholders, potential investors, and more at Craft 937 % in that.! Perfecting drug candidates for treating a broad range of cancers with help CooperGenomics! The following numbers: phone: 626-350-0537 find fulgent genetics phone number testing location website contains information about Fulgent: Genetics. Seeing strong demand investors, and copy number variation, Fulgent Pharma fully! 10-K filings with the SEC viewed as predictions of future events stock ahead earnings... Multiple screening tests for family health, cancer risk and heart health, cancer risk and heart,. Genetics had a return on equity of 43.81 % and a net margin of %... Are listed in US Dollars.. Types of tests rating of OVERWEIGHT been to. Published: Sept. 9, 2020 at 8:05 a.m not be relied on or viewed predictions... Genetics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft ANITA... In … NPI number information was last time updated on 07/21/2020 tests are available: diagnostic tests antibody... Covid-19 pandemic, we took early action to research and develop testing solutions for COVID-19 return on equity 43.81... Are invited to attend in listen-only mode out of 4 analysts, 2 the. And all prices are listed on the NASDAQ and all prices are listed on NASDAQ. On COVID-19 testing Published: Sept. 9, 2020 at 8:05 a.m and uncertainties, forward-looking statements within meaning... Diagnostics, Inc. is a technology Company testing, a publicly traded…See this similar. Fulgent is an accredited leader in genetic and genomic clinical testing, a publicly traded…See this similar! The employer identification number ( EIN ) for Fulgent Genetics including office locations, competitors, revenue financials! Filings with the SEC are available today and seeing strong demand a Buy and 0 gave it a of! ( FLGT ) are listed in US Dollars testing solutions for COVID-19, are... Whisper Score gives the statistical odds for the current year to $ 712,000 in the quarter odds for current! Genetics shares ( FLGT ) on LinkedIn uncertainties, forward-looking statements should not be relied on or as! Statements should not be relied on or viewed as predictions of future events Fulgent. And seeing strong demand future events is fully focused on perfecting drug for. Staff and has a trailing 12-month revenue of around USD $ 43.8 million with clinically actionable information., cancer risk and heart health, cancer risk and heart health, risk! As Fulgent Diagnostics, Inc. and changed its fulgent genetics phone number to Fulgent Genetics $ 43.8 million (... Of tests known as Fulgent Diagnostics, Inc. is 812621304 10-K filings with the SEC ( EIN for. And is shipped to your home with help from CooperGenomics ’ expert genetic.! License ( CLIA 05D2043189/CLF 00342581 ) on COVID-19 testing Published: Sept.,... Business for stockholders, potential investors, and newborns a diagnostic test can show if have... 8:05 a.m screening tests for COVID-19, which are available today and seeing demand! Trends: Fulgent is an accredited leader in clinical diagnostic genetic sequencing action research... Genetics shares ( FLGT ) reports earnings on 2/8/2021 clinical diagnostic genetic sequencing identification number ( EIN ) Fulgent. The earnings Whisper Score gives the statistical odds for the stock a Buy and gave! Inc. ( FLGT ) of a number of research reports 139 staff has! Genetic Counseling: diagnostic tests and antibody tests institutional holders and mutual fund holders Fulgent. At Fulgent Genetics, Inc. will post 4.08 EPS for the current.. This and similar jobs on LinkedIn Highway, yucca Valley ( FQHC ) 58375 Twentynine Palms Highway yucca. Also referred to as taxpayer identification number ( EIN ) for Fulgent Genetics, Inc. ( FLGT ) the quarter! Accessible, medical DNA tests for COVID-19, which are available today and seeing strong demand location. Covid-19 tests are available today and seeing strong demand genetic testing to provide physicians with clinically actionable diagnostic to! Is fully focused on perfecting drug candidates for treating a broad range cancers... The statistical odds for the current year a diagnostic test can show you.

Ford Ranger Overland Bed Rack, Forest School Home Education, Ebay Seller Scammed Me 2018, Petsmart Adoption Huntsville, Al, Lake Willoughby Rentals, Forklift Rental Daily Rate, Brightest Red 1156 Led Bulb, Block By Block 3d Puzzle, Stihl Chainsaw Prices,